rheumatoid arthritis
Conditions
Interventions
treatment group:hUC-MSCs, IFN-?
Sponsors
Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital; 2. Patients of RA, to be aged 18 years to 65 years old; 3. All patients fulfilled the classification criteria (ACR21987) for rheumatoid arthritis; 4. All patients fulfilled hormone-dependent or through formal use of methotrexate / leflunomide / hydroxychloroquine sulfate / sulfasalazine / tripterygium and / or at least one kind of TNF-a inhibitor, is still high disease activity or can not be tolerated.
Exclusion criteria
Exclusion criteria: 1. Patients with uncorrected disease, such as advanced cancer or other terminal illness, the prospective survival period less than 28 days; 2. Patients in the foreseeable dying state; 3. Have the bone marrow, lungs, liver, pancreas, or small bowel transplantation history; 4. Have severe heart and lung failure, or irreversible damage or failure of other major organs; 5. Uncontrolled infection; 6. Patient participating or having participated in a clinical trial with another investigational drug Within 30 days before the start of this clinical trial; 7. Patient is pregnant or nursing; 8. History of patient is allergic to biological products; 9. HIV infected associated with the recent CD4+ cell count =50/mm3; 10. viral hepatitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DAS28;HAQ;CRP;ESR;Treg;Th17;IFN-?; | — |
Countries
China
Contacts
Public ContactXiang Xu
Department of Rheumatology and Immunology, Daping Hospital, Third Military Medical University, Chongqing
Outcome results
None listed